CA2306646A1 - Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires - Google Patents
Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires Download PDFInfo
- Publication number
- CA2306646A1 CA2306646A1 CA002306646A CA2306646A CA2306646A1 CA 2306646 A1 CA2306646 A1 CA 2306646A1 CA 002306646 A CA002306646 A CA 002306646A CA 2306646 A CA2306646 A CA 2306646A CA 2306646 A1 CA2306646 A1 CA 2306646A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- methylsulfonyl
- inhibitor
- dimethyl
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention propose une combinaison de médicaments contenant un inhibiteur de HMG-CoA réductase, associé à un inhibiteur de COX-2, servant à traiter, prévenir et/ou réduire les risques de développement de l'athérosclérose et d'apparition d'incidents pathologiques liés à l'athérosclérose.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6269197P | 1997-10-22 | 1997-10-22 | |
US60/062,691 | 1997-10-22 | ||
GB9806688.9 | 1998-03-27 | ||
GBGB9806688.9A GB9806688D0 (en) | 1998-03-27 | 1998-03-27 | Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease |
PCT/US1998/021901 WO1999020110A1 (fr) | 1997-10-22 | 1998-10-16 | Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2306646A1 true CA2306646A1 (fr) | 1999-04-29 |
Family
ID=26313383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002306646A Abandoned CA2306646A1 (fr) | 1997-10-22 | 1998-10-16 | Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1024696A4 (fr) |
JP (1) | JP2001520174A (fr) |
AU (1) | AU753657B2 (fr) |
CA (1) | CA2306646A1 (fr) |
WO (1) | WO1999020110A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6620834B1 (en) * | 1999-07-02 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
JP2003523330A (ja) | 2000-02-04 | 2003-08-05 | チルドレンズ・ホスピタル・リサーチ・ファウンデイション | アテローム性動脈硬化症および関連疾患のための脂質加水分解治療 |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
DK1303265T3 (da) | 2000-07-20 | 2007-11-12 | Lauras As | Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS |
AU2002213050A1 (en) * | 2000-10-06 | 2002-04-15 | F. Timothy Guilford | A combination and method of treatment of cancer utilizing a cox-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa) reductase inhibitor |
US6534540B2 (en) | 2000-10-06 | 2003-03-18 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor |
WO2002094021A1 (fr) * | 2000-10-06 | 2002-11-28 | Probiochem, Llc | Combinaison et methode de traitement par un inhibiteur de la cox-2, un inhibiteur de la hmg-coa et la cystine pour ameliorer la fonction du glutathion |
JP4092203B2 (ja) | 2000-12-21 | 2008-05-28 | ニトロメッド,インク. | 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
WO2004006919A1 (fr) * | 2002-07-11 | 2004-01-22 | Sankyo Company, Limited | Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine |
JP4611622B2 (ja) * | 2002-07-11 | 2011-01-12 | 第一三共株式会社 | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 |
EP2808015A1 (fr) | 2005-05-31 | 2014-12-03 | Mylan Laboratories, Inc | Compositions comportant du nebivolol |
US20070037797A1 (en) * | 2005-08-15 | 2007-02-15 | Hellstrom Harold R | Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events |
US8026377B2 (en) * | 2005-11-08 | 2011-09-27 | Ranbaxy Laboratories, Limited | Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
EP2770978B1 (fr) | 2011-10-28 | 2018-01-10 | Vitalis LLC | Compositions anti-bouffée |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112639A0 (en) * | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
WO1996039144A1 (fr) * | 1995-06-06 | 1996-12-12 | Procyte Corporation | Complexes cuivreux stables utilises comme substances a activite therapeutique |
TR199801731T2 (xx) * | 1996-03-05 | 1999-02-22 | Children's Hospital Medical Center | Siklooksijenaz önleyicileri olarak merkapto türevleri. |
-
1998
- 1998-10-16 EP EP98957328A patent/EP1024696A4/fr not_active Withdrawn
- 1998-10-16 JP JP2000516533A patent/JP2001520174A/ja not_active Withdrawn
- 1998-10-16 CA CA002306646A patent/CA2306646A1/fr not_active Abandoned
- 1998-10-16 WO PCT/US1998/021901 patent/WO1999020110A1/fr not_active Application Discontinuation
- 1998-10-16 AU AU13612/99A patent/AU753657B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP1024696A4 (fr) | 2004-07-14 |
AU753657B2 (en) | 2002-10-24 |
EP1024696A1 (fr) | 2000-08-09 |
WO1999020110A1 (fr) | 1999-04-29 |
JP2001520174A (ja) | 2001-10-30 |
AU1361299A (en) | 1999-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6245797B1 (en) | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease | |
US6232315B1 (en) | Method for treating inflammatory diseases by administering a thrombin inhibitor | |
US6136804A (en) | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions | |
AU753657B2 (en) | Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease | |
KR20050043744A (ko) | 시클로옥시게나제-2 억제제/히스톤 데아세틸라제 억제제복합제제 | |
AU753079B2 (en) | Combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor | |
US20020016342A1 (en) | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor | |
US20020115689A1 (en) | Combination therapy for treating neurodegenerative disease | |
CA2322824A1 (fr) | Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes | |
WO2001022962A1 (fr) | Combinaison anti-hypercholesterolemique | |
WO2003094924A1 (fr) | Therapie de combinaison destinee a traiter des maladies a mediation par cyclooxygenase-2 chez des malades presentant un risque d'accident cardiovasculaire thrombotique | |
US20060079579A1 (en) | Combinations of valsartan with cox-2 inhibitors | |
US6440967B1 (en) | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E | |
WO2003039542A1 (fr) | Therapie combinee pour le traitement de la maladie d'alzheimer | |
CA2327585A1 (fr) | Utilisation d'un inhibiteur de cox-2 et d'un antagoniste du recepteur nk-1 dans le traitement de l'inflammation | |
US20040097573A1 (en) | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | |
US20030035795A1 (en) | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | |
AU715676B2 (en) | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | |
US20050215611A1 (en) | Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |